LEADERSHIP
Saturn Sade Sati, its phases and effects
Sani Sade Sati, or Sade Sati, is a seven-and-a-half-year period of uncertainty and hardship. Saturn or Shani enters the zodiac sign before the janma rasi (birth chart moon sign) begins…
Your Trusted Source for Accurate and Timely Updates!
Just for You
Akshay Sharma: A Giver, Building Legacy with Soul, Not Spotlight
In today’s world, where chasing fame, followers, and funding defines success, Akshay Sharma chooses to…
Lasted LEADERSHIP
Akshay Sharma: A Giver, Building Legacy with Soul, Not Spotlight
In today’s world, where chasing fame, followers, and funding defines success, Akshay Sharma chooses to walk the lesser-traveled road; one…
Unveiling the Unsung Heroes: Celebrating Black and Brown Women in the UK Suffrage Movement! By Dawn-Maria France
Photo: Sophia Duleep Singh Image source en.wikipedia.org The fight for women's suffrage in the United Kingdom often brings to mind…
What truly stops you from Success?
Even in a world with limitless opportunities, many still struggle to achieve financial independence. The journey is often presented with…
The Man Who Knows and Lives Everything Is Energy—And Beyond Meet the Mystical, Stellar Jeweler and Mentor to the Stars: Guruji Shrii Arnav A Legacy Written in the Stars, Crowned in the House of Lords
Energy Essence or Energy Essential Quintessentially British-The Grandmaster Guruji Shrii Arnav embodying the eternal philosophy of Keep Walking and you…
Saturn Sade Sati, its phases and effects
Sani Sade Sati, or Sade Sati, is a seven-and-a-half-year period of uncertainty and hardship. Saturn or Shani enters the zodiac…
Driving Digital Evolution: The Webhook Media Story
In the bustling landscape of global marketing, one agency has emerged as a trailblazer, seamlessly merging digital marketing with public…
Meta Handed $100 Million Fine in Ireland Over Password Storage
Ireland’s data protection watchdog fined Meta Platforms after the Facebook and Instagram owner stored passwords of some social media users…
Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion
Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.